Our STN: BL 125347/575

**SUPPLEMENT APPROVAL**
December 17, 2025

GlaxoSmithKline Biologicals
Attention: Aimee Sibelle Ngankeu Sandjong
14200 Shady Grove Road
VR1500
Rockville, MD 20850-7464

Dear Ms. Ngankeu Sandjong:

We have approved your request received July 30, 2025, to supplement your Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) [HIBERIX] to include an update to the Package Insert to remove information from several sections, where appropriate, regarding the vial-vial presentation due to its discontinuation, and minor revisions to the carton label.

## LABELING

We hereby approve the draft content of labeling: Package Insert submitted under amendment 6, dated December 12, 2025, and the draft carton label submitted under amendment 7, dated December 16, 2025.

## CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the Package Insert submitted on December 12, 2025. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

## CARTON AND CONTAINER LABELS

Please electronically submit a final printed carton label identical to the carton label submitted on December 16, 2025, according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications* at

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-certain-human-pharmaceutical-product-applications.

All final labeling should be submitted as Product Correspondence to this BLA STN BL 125347 at the time of use and include implementation information on Form FDA 356h.

**ADVERTISING AND PROMOTIONAL LABELING**

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

For each pending supplemental application for this BLA that includes proposed revised labeling, please submit an amendment to update the proposed revised labeling with the changes approved today.

We will include information contained in the above-referenced supplement in your BLA file.

Sincerely,

Douglas Pratt, MD, MPH
Deputy Director
Division of Clinical and Toxicology Review
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research